New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
07:12 EDTTSRO, MYGNMyriad Genetics announces HRD collaboration with TESARO
Myriad Genetics (MYGN) announced that Tesaro (TSRO) will use Myriad's novel HRD, or homologous recombination deficiency, test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase, or PARP, inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed.
News For MYGN;TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
10:54 EDTTSROTESARO label not expected to limit usage, says Mizuho
Subscribe for More Information
10:34 EDTTSROLadenburg reiterates Buy on OPKO after Varubi approval
Subscribe for More Information
08:50 EDTTSROOPKO Health rises after TESARO gets FDA approval for VARUBI
Shares of both OPKO Health (OPK) and TESARO (TSRO) are higher in pre-market trading after the latter announced earlier that the FDA has approved VARUBI in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. An intravenous formulation of rolapitant is also being developed. TESARO licensed exclusive rights for the development, manufacture, commercialization and distribution of VARUBI from OPKO Health. In pre-market trading, TESARO shares rose 4.3% to $53.90, while OPKO shares gained 4.5% to $11.30.
08:10 EDTTSROTESARO announces FDA approval of Varubi
TESARO announced that the FDA has approved Varubi in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Varubi is a selective and competitive antagonist of human substance P/neurokinin 1, or NK-1, receptors, with a plasma half-life of approximately seven days. Results from three Phase 3 trials of Varubi demonstrated a significant reduction in episodes of vomiting or use of rescue medication during the 25 to 120 hour period following administration of highly emetogenic and moderately emetogenic chemotherapy regimens. In addition, patients who received Varubi reported experiencing less nausea that interfered with normal daily life and fewer episodes of vomiting or retching over multiple cycles of chemotherapy. A 180 milligram dose of Varubi is to be administered approximately one to two hours prior to chemotherapy administration in combination with a 5-HT3 receptor antagonist and dexamethasone. No dosage adjustment is required for dexamethasone, a CYP3A4 substrate, when administering Varubi.
September 1, 2015
10:05 EDTTSROOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 8point3 Energy (CAFD) initiated with an Equal Weight at Barclays... AMAG Pharmaceuticals (AMAG) initiated with an Outperform at Raymond James... Acadia (ACHC) initiated with an Outperform at Leerink... Acorda Therapeutics (ACOR) initiated with a Market Perform at Raymond James... Alexion (ALXN) initiated with a Strong Buy at Raymond James... Amedisys (AMED) initiated with an Outperform at Wells Fargo... Amgen (AMGN) initiated with a Market Perform at Raymond James... Amplify Snack Brands (BETR) initiated with a Neutral at Credit Suisse... BioMarin (BMRN) initiated with an Outperform at Raymond James... Biogen (BIIB) initiated with a Strong Buy at Raymond James... Celgene (CELG) initiated with a Strong Buy at Raymond James... CoreLogic (CLGX) initiated with a Neutral at SunTrust... Digi International (DGII) initiated with an Overweight at Stephens... First Solar (FSLR) initiated with an Overweight at Barclays... LHC Group (LHCG) initiated with an Outperform at Wells Fargo... Lancaster Colony (LANC) initiated with a Buy at BB&T... McCormick (MKC) initiated with a Buy at BB&T... NephroGenex (NRX) initiated with a Buy at H.C. Wainwright... Omega Protein (OME) initiated with a Hold at BB&T... Preferred Apartment (APTS) initiated with an Outperform at FBR Capital... Qorvo (QRVO) initiated with an Outperform at CLSA... Regeneron (REGN) initiated with an Outperform at Raymond James... Skyworks (SWKS) initiated with an Outperform at CLSA... SunPower (SPWR) initiated with an Equal Weight at Barclays... TESARO (TSRO) initiated with a Strong Buy at Raymond James... Ultragenyx (RARE) initiated with an Outperform at Raymond James... VEREIT (VER) initiated with a Buy at Goldman... Westmoreland (WLB) initiated with an Outperform at BMO Capital.
August 31, 2015
19:27 EDTTSROTESARO initiated with a Strong Buy at Raymond James
Subscribe for More Information
August 25, 2015
07:41 EDTMYGNMyriad Genetics upgraded on positive risk/reward at Wells Fargo
Subscribe for More Information
06:22 EDTMYGNMyriad Genetics upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use